BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 36901858)

  • 1. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
    Tzeng HT; Huang YJ
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducing vascular normalization: A promising strategy for immunotherapy.
    Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
    Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
    Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
    Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
    Qian C; Liu C; Liu W; Zhou R; Zhao L
    Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
    Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W
    Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of the vasculature for treatment of cancer and other diseases.
    Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
    Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor vascularization: promising strategies for vascular normalization.
    Zheng R; Li F; Li F; Gong A
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
    Lee WS; Yang H; Chon HJ; Kim C
    Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
    Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
    Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
    Li S; Zhang Q; Hong Y
    Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes.
    O'Melia MJ; Rohner NA; Thomas SN
    Tissue Eng Part A; 2022 Sep; 28(17-18):781-794. PubMed ID: 35442085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
    Ramjiawan RR; Griffioen AW; Duda DG
    Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
    Fukumura D; Jain RK
    Microvasc Res; 2007; 74(2-3):72-84. PubMed ID: 17560615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune therapy and tumor angiogenesis].
    Takakura N
    Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
    Missiaen R; Mazzone M; Bergers G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
    Majidpoor J; Mortezaee K
    Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
    Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
    Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
    J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual role of endothelial
    Kabir AU; Subramanian M; Lee DH; Wang X; Krchma K; Wu J; Naismith T; Halabi CM; Kim JY; Pulous FE; Petrich BG; Kim S; Park HC; Hanson PI; Pan H; Wickline SA; Fremont DH; Park C; Choi K
    Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.